Abstract
Uric acid (UA) transporters, including urate transporter 1 (URAT1), glucose transporter 9 (GLUT9), and ATP-binding cassette subfamily G member 2 (ABCG2), are involved in hyperuricemia. A novel selective urate reabsorption inhibitor, developed in Japan, reduces serum UA levels by selectively inhibiting URAT1. The Japanese Society of Gout and Nucleic Acid Metabolism published "Guidelines for the Management of Hyperuricemia and Gout (3rd edition, 2022-Supplementary Edition-)" in March 2022. This guideline provides valuable information for decision-making in clinical management of hyperuricemia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings for Annual Meeting of The Japanese Pharmacological Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
